Influence of Receptor Polymorphisms on the Response to alpha-Adrenergic Receptor Blockers in Pheochromocytoma Patients

Annika M A Berends; Mathieu S Bolhuis; Ilja M Nolte; Edward Buitenwerf; Thera P Links; Henri J L M Timmers; Richard A Feelders; Elisabeth M W Eekhoff; Eleonora P M Corssmit; Peter H Bisschop; Harm R Haak; Ron H N van Schaik; Samira El Bouazzaoui; Bob Wilffert; Michiel N Kerstens

doi:10.3390/biomedicines10040896

Influence of Receptor Polymorphisms on the Response to alpha-Adrenergic Receptor Blockers in Pheochromocytoma Patients

Annika M A Berends^*, Mathieu S Bolhuis, Ilja M Nolte, Edward Buitenwerf, Thera P Links, Henri J L M Timmers, Richard A Feelders, Elisabeth M W Eekhoff, Eleonora P M Corssmit, Peter H Bisschop, Harm R Haak, Ron H N van Schaik, Samira El Bouazzaoui, Bob Wilffert, Michiel N Kerstens

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

2 Citations (Scopus)

93 Downloads (Pure)

Abstract

Background: Presurgical treatment with an α-adrenergic receptor blocker is recommended to antagonize the catecholamine-induced α-adrenergic receptor mediated vasoconstriction in patients with pheochromocytoma or sympathetic paraganglioma (PPGL). There is, however, a considerable interindividual variation in the dose-response relationship regarding the magnitude of blood pressure reduction or the occurrence of side effects. We hypothesized that genetically determined differences in α-adrenergic receptor activity contribute to this variability in dose-response relationship.

Methods: Thirty-one single-nucleotide polymorphisms (SNPs) of the α1A, α1B, α1D adrenoreceptor (ADRA1A, ADRA1B, ADRA1D) and α2A, α2B adrenoreceptor (ADRA2A, ADRA2B) genes were genotyped in a group of 116 participants of the PRESCRIPT study. Haplotypes were constructed after determining linkage disequilibrium blocks.

Results: The ADRA1B SNP rs10515807 and the ADRA2A SNPs rs553668/rs521674 were associated with higher dosages of α-adrenergic receptor blocker (p < 0.05) and with a higher occurrence of side effects (rs10515807) (p = 0.005). Similar associations were found for haplotype block 6, which is predominantly defined by rs10515807.

Conclusions: This study suggests that genetic variability of α-adrenergic receptor genes might be associated with the clinically observed variation in beneficial and adverse therapeutic drug responses to α-adrenergic receptor blockers. Further studies in larger cohorts are needed to confirm our observations.

Original language	English
Article number	896
Number of pages	15
Journal	Biomedicines
Volume	10
Issue number	4
DOIs	https://doi.org/10.3390/biomedicines10040896
Publication status	Published - 13-Apr-2022

Keywords

pheochromocytoma
paraganglioma
single nucleotide polymorphism
adrenergic receptor
alpha-adrenergic receptor blocker
pharmacogenetics
personalized medicine
GENOME-WIDE ASSOCIATION
GENETIC-VARIATION
BLOOD-PRESSURE
ALPHA(1B)-ADRENERGIC RECEPTOR
ALPHA(2B)-ADRENERGIC RECEPTOR
ALPHA-1-ADRENERGIC RECEPTOR
FASTING GLUCOSE
ADRA2A
VARIANTS
HYPERTENSION

Access to Document

10.3390/biomedicines10040896Licence: CC BY

Influence of Receptor Polymorphisms on the Response to α-Adrenergic Receptor Blockers in Pheochromocytoma PatientsFinal publisher's version, 662 KBLicence: CC BY

Handle.net

Persistent link

Cite this

Berends, A. M. A., Bolhuis, M. S., Nolte, I. M., Buitenwerf, E., Links, T. P., Timmers, H. J. L. M., Feelders, R. A., Eekhoff, E. M. W., Corssmit, E. P. M., Bisschop, P. H., Haak, H. R., van Schaik, R. H. N., El Bouazzaoui, S., Wilffert, B., & Kerstens, M. N. (2022). Influence of Receptor Polymorphisms on the Response to alpha-Adrenergic Receptor Blockers in Pheochromocytoma Patients. Biomedicines, 10(4), Article 896. https://doi.org/10.3390/biomedicines10040896

@article{1d567665dc6848b6b8b8a3b3310b28df,

title = "Influence of Receptor Polymorphisms on the Response to alpha-Adrenergic Receptor Blockers in Pheochromocytoma Patients",

abstract = "Background: Presurgical treatment with an α-adrenergic receptor blocker is recommended to antagonize the catecholamine-induced α-adrenergic receptor mediated vasoconstriction in patients with pheochromocytoma or sympathetic paraganglioma (PPGL). There is, however, a considerable interindividual variation in the dose-response relationship regarding the magnitude of blood pressure reduction or the occurrence of side effects. We hypothesized that genetically determined differences in α-adrenergic receptor activity contribute to this variability in dose-response relationship.Methods: Thirty-one single-nucleotide polymorphisms (SNPs) of the α1A, α1B, α1D adrenoreceptor (ADRA1A, ADRA1B, ADRA1D) and α2A, α2B adrenoreceptor (ADRA2A, ADRA2B) genes were genotyped in a group of 116 participants of the PRESCRIPT study. Haplotypes were constructed after determining linkage disequilibrium blocks.Results: The ADRA1B SNP rs10515807 and the ADRA2A SNPs rs553668/rs521674 were associated with higher dosages of α-adrenergic receptor blocker (p < 0.05) and with a higher occurrence of side effects (rs10515807) (p = 0.005). Similar associations were found for haplotype block 6, which is predominantly defined by rs10515807.Conclusions: This study suggests that genetic variability of α-adrenergic receptor genes might be associated with the clinically observed variation in beneficial and adverse therapeutic drug responses to α-adrenergic receptor blockers. Further studies in larger cohorts are needed to confirm our observations.",

keywords = "pheochromocytoma, paraganglioma, single nucleotide polymorphism, adrenergic receptor, alpha-adrenergic receptor blocker, pharmacogenetics, personalized medicine, GENOME-WIDE ASSOCIATION, GENETIC-VARIATION, BLOOD-PRESSURE, ALPHA(1B)-ADRENERGIC RECEPTOR, ALPHA(2B)-ADRENERGIC RECEPTOR, ALPHA-1-ADRENERGIC RECEPTOR, FASTING GLUCOSE, ADRA2A, VARIANTS, HYPERTENSION",

author = "Berends, {Annika M A} and Bolhuis, {Mathieu S} and Nolte, {Ilja M} and Edward Buitenwerf and Links, {Thera P} and Timmers, {Henri J L M} and Feelders, {Richard A} and Eekhoff, {Elisabeth M W} and Corssmit, {Eleonora P M} and Bisschop, {Peter H} and Haak, {Harm R} and {van Schaik}, {Ron H N} and {El Bouazzaoui}, Samira and Bob Wilffert and Kerstens, {Michiel N}",

year = "2022",

month = apr,

day = "13",

doi = "10.3390/biomedicines10040896",

language = "English",

volume = "10",

journal = "Biomedicines",

issn = "2227-9059",

publisher = "MDPI AG",

number = "4",

}

Berends, AMA , Bolhuis, MS , Nolte, IM, Buitenwerf, E, Links, TP, Timmers, HJLM, Feelders, RA, Eekhoff, EMW, Corssmit, EPM, Bisschop, PH, Haak, HR, van Schaik, RHN, El Bouazzaoui, S, Wilffert, B & Kerstens, MN 2022, 'Influence of Receptor Polymorphisms on the Response to alpha-Adrenergic Receptor Blockers in Pheochromocytoma Patients', Biomedicines, vol. 10, no. 4, 896. https://doi.org/10.3390/biomedicines10040896

TY - JOUR

T1 - Influence of Receptor Polymorphisms on the Response to alpha-Adrenergic Receptor Blockers in Pheochromocytoma Patients

AU - Berends, Annika M A

AU - Bolhuis, Mathieu S

AU - Nolte, Ilja M

AU - Buitenwerf, Edward

AU - Links, Thera P

AU - Timmers, Henri J L M

AU - Feelders, Richard A

AU - Eekhoff, Elisabeth M W

AU - Corssmit, Eleonora P M

AU - Bisschop, Peter H

AU - Haak, Harm R

AU - van Schaik, Ron H N

AU - El Bouazzaoui, Samira

AU - Wilffert, Bob

AU - Kerstens, Michiel N

PY - 2022/4/13

Y1 - 2022/4/13

N2 - Background: Presurgical treatment with an α-adrenergic receptor blocker is recommended to antagonize the catecholamine-induced α-adrenergic receptor mediated vasoconstriction in patients with pheochromocytoma or sympathetic paraganglioma (PPGL). There is, however, a considerable interindividual variation in the dose-response relationship regarding the magnitude of blood pressure reduction or the occurrence of side effects. We hypothesized that genetically determined differences in α-adrenergic receptor activity contribute to this variability in dose-response relationship.Methods: Thirty-one single-nucleotide polymorphisms (SNPs) of the α1A, α1B, α1D adrenoreceptor (ADRA1A, ADRA1B, ADRA1D) and α2A, α2B adrenoreceptor (ADRA2A, ADRA2B) genes were genotyped in a group of 116 participants of the PRESCRIPT study. Haplotypes were constructed after determining linkage disequilibrium blocks.Results: The ADRA1B SNP rs10515807 and the ADRA2A SNPs rs553668/rs521674 were associated with higher dosages of α-adrenergic receptor blocker (p < 0.05) and with a higher occurrence of side effects (rs10515807) (p = 0.005). Similar associations were found for haplotype block 6, which is predominantly defined by rs10515807.Conclusions: This study suggests that genetic variability of α-adrenergic receptor genes might be associated with the clinically observed variation in beneficial and adverse therapeutic drug responses to α-adrenergic receptor blockers. Further studies in larger cohorts are needed to confirm our observations.

AB - Background: Presurgical treatment with an α-adrenergic receptor blocker is recommended to antagonize the catecholamine-induced α-adrenergic receptor mediated vasoconstriction in patients with pheochromocytoma or sympathetic paraganglioma (PPGL). There is, however, a considerable interindividual variation in the dose-response relationship regarding the magnitude of blood pressure reduction or the occurrence of side effects. We hypothesized that genetically determined differences in α-adrenergic receptor activity contribute to this variability in dose-response relationship.Methods: Thirty-one single-nucleotide polymorphisms (SNPs) of the α1A, α1B, α1D adrenoreceptor (ADRA1A, ADRA1B, ADRA1D) and α2A, α2B adrenoreceptor (ADRA2A, ADRA2B) genes were genotyped in a group of 116 participants of the PRESCRIPT study. Haplotypes were constructed after determining linkage disequilibrium blocks.Results: The ADRA1B SNP rs10515807 and the ADRA2A SNPs rs553668/rs521674 were associated with higher dosages of α-adrenergic receptor blocker (p < 0.05) and with a higher occurrence of side effects (rs10515807) (p = 0.005). Similar associations were found for haplotype block 6, which is predominantly defined by rs10515807.Conclusions: This study suggests that genetic variability of α-adrenergic receptor genes might be associated with the clinically observed variation in beneficial and adverse therapeutic drug responses to α-adrenergic receptor blockers. Further studies in larger cohorts are needed to confirm our observations.

KW - pheochromocytoma

KW - paraganglioma

KW - single nucleotide polymorphism

KW - adrenergic receptor

KW - alpha-adrenergic receptor blocker

KW - pharmacogenetics

KW - personalized medicine

KW - GENOME-WIDE ASSOCIATION

KW - GENETIC-VARIATION

KW - BLOOD-PRESSURE

KW - ALPHA(1B)-ADRENERGIC RECEPTOR

KW - ALPHA(2B)-ADRENERGIC RECEPTOR

KW - ALPHA-1-ADRENERGIC RECEPTOR

KW - FASTING GLUCOSE

KW - ADRA2A

KW - VARIANTS

KW - HYPERTENSION

U2 - 10.3390/biomedicines10040896

DO - 10.3390/biomedicines10040896

M3 - Article

C2 - 35453646

SN - 2227-9059

VL - 10

JO - Biomedicines

JF - Biomedicines

IS - 4

M1 - 896

ER -

Influence of Receptor Polymorphisms on the Response to alpha-Adrenergic Receptor Blockers in Pheochromocytoma Patients

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this